Stanford study raises Cas9 immunogenicity concerns

A new study published Friday on the preprint server bioRxiv suggests many people may have pre-existing immunity to the Cas9 enzymes commonly used in CRISPR-based therapeutics, raising questions

Read the full 287 word article

How to gain access

Continue reading with a
two-week free trial.